Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Taysha Gene Therapies Q2 EPS $(0.09) Misses $(0.08) Estimate, Sales $1.986M Beat $1.765M Estimate

Author: Benzinga Newsdesk | August 12, 2025 08:01am
Taysha Gene Therapies (NASDAQ:TSHA) reported quarterly losses of $(0.09) per share which missed the analyst consensus estimate of $(0.08) by 9.76 percent. This is unchanged from the same period last year. The company reported quarterly sales of $1.986 million which beat the analyst consensus estimate of $1.765 million by 12.51 percent. This is a 78.60 percent increase over sales of $1.112 million the same period last year.

Posted In: TSHA


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist